Consun Pharmaceutical Group Limited

HKSE 1681.HK

Consun Pharmaceutical Group Limited Market Capitalization on January 28, 2025: USD 834.11 M

Consun Pharmaceutical Group Limited Market Capitalization is USD 834.11 M on January 28, 2025, a 50.18% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
  • Consun Pharmaceutical Group Limited 52-week high Market Capitalization is USD 919.27 M on November 12, 2024, which is 10.21% above the current Market Capitalization.
  • Consun Pharmaceutical Group Limited 52-week low Market Capitalization is USD 537.03 M on February 05, 2024, which is -35.62% below the current Market Capitalization.
  • Consun Pharmaceutical Group Limited average Market Capitalization for the last 52 weeks is USD 687.95 M.
Key data
Date Market Capitalization Share Price Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S)
Market news
Loading...
SV Wall Street
HKSE: 1681.HK

Consun Pharmaceutical Group Limited

Description

Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography. The company also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; and Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis. In addition, it offers Gyn Antidysmenorrheic tablets for the treatment of irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion for staphylococcus aureus, Candida albicans, and escherichia coli in the feminine vaginal. Further, the company provides bone-setting liquid; Yunxiang analgesic tincture for treatment of rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; and Shiduqing capsules and tablets, and Paeonol ointment for skin disease. Additionally, it offers hepatobiliary, gastroenterology, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.

Similar companies

1666.HK

Tong Ren Tang Technologies Co. Ltd.

USD 0.63

-1.24%

1515.HK

China Resources Medical Holdings Company Limited

USD 0.48

-1.60%

1513.HK

Livzon Pharmaceutical Group Inc.

USD 3.38

-0.40%

StockViz Staff

February 4, 2025

Any question? Send us an email